Advances in PH Journal
Featuring Highlights from the 3rd World Symposium on Pulmonary Hypertension, Autumn 2003 (Vol 2, No 3)
- Editor's Memo- Presenting Highlights from Two Exceptional Meetings on Pulmonary Hypertension
Two exceptional meetings this year offered rare opportunities for clinicians involved with pulmonary arterial hypertension to evaluate the progress made in treating this disease.
- Profiles in Pulmonary Hypertension- Cardiologist Nazzareno Galiè: A Guiding Light for Worldwide Consensus on Pulmonary Hypertension
If anyone is keeping track of the number of scientific publications on pulmonary arterial hypertension (PAH), pulmonary embolism, chronic heart failure, and heart transplantation authored or coauthored by Nazzareno Galiè, MD, the total has reached more than 280.
- NIH Conference Charts Future Directions in Identifying Patients at Risk for Primary Pulmonary Hypertension
As diagnostic and treatment approaches to pulmonary hypertension evolve over the next few years, clinicians may look back at an NIH conference held earlier this year as a watershed, a meeting where many of the new directions in care were charted.
- A Who’s Who from the NIH Conference on Primary Pulmonary Hypertension
A conference earlier this year sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health drew experts from around the country and Canada to discuss new directions in research.
- Recapping Highlights from the Third World Symposium on Pulmonary Arterial Hypertension, Venice, Italy, June 23-25, 2003
As the broad range of topics suggests, the Third World Symposium on Pulmonary Arterial Hypertension (PAH) addressed many of the issues of overriding importance to clinicians involved with treatment of the disease.
- Task Force on Diagnosis and Assessment: Identifying the Most Useful Tools
A diagnostic algorithm that is accepted among experienced centers (Pull-Out, next page) can guide the evaluation of pulmonary hypertension. Like all guidelines, the algorithm may be modified according to specific clinical circumstances.
- Overview of Genetics as presented at the PAH Symposium in Venice
Medical scientists have achieved three major goals proposed by the 1998 Evian task force on the genetics of pulmonary hypertension. First, mutations in the gene that codes for bone morphogenetic protein receptor 2 (BMPR2) are linked to familial primary pulmonary hypertension.
- Pathophysiology of Pulmonary Hypertension: Recognizing Triggers of the Disease
It is unclear whether the various types of PAH share a common pathogenic mechanism. Although our understanding of the pathobiological changes underlying PAH has progressed rapidly over the past few years, it is still impossible to classify patients on a pathogenic basis and to define therapeutic approach accordingly.
- Report From the Task Force on Medical Treatments
The recent clinical trials with novel compounds have produced a tremendous increase of both knowledge and therapeutic options in patients with pulmonary arterial hypertension (PAH).
- Acute Vasodilator Testing in PAH
Vasoconstriction of pulmonary arteries is recognized as an important component of the pathogenesis of pulmonary arterial hypertension (PAH).
- Transplantation and Thromboendarterectomy for Severe Pulmonary Hypertension: Report from the Transplant and Interventions Task Force
Recent advances in medical and interventional approaches to the management of patients with pulmonary arterial hypertension (PAH) have had a marked effect on the policy toward referring such patients for transplantation and there has been a reduction of 50% in numbers of patients with primary pulmonary hypertension (PPH) undergoing transplantation over the last decade.
- One on One Interview- Seeking a Consensus on PH: Challenges Left by the Venice Symposium
Commentary on the Venice Meeting, featuring an interview of Nazzareno Galiè, MD, one of the organizers of the Third World Symposium on Pulmonary Hypertension. Victor Tapson, MD, is Editor-in-Chief of Advances in Pulmonary Hypertension.